ArticleFrontiers in immunology2023

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.

Guiyuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.